Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized Study Comparing Oral Valganciclovir Versus Intravenous Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation.

X
Trial Profile

Multicenter, Randomized Study Comparing Oral Valganciclovir Versus Intravenous Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valganciclovir (Primary) ; Ganciclovir
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONVINCE
  • Most Recent Events

    • 31 Mar 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
    • 23 Mar 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 14 Jun 2011 Additional locations (Austria,Germany, Spain) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top